Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

SS Ramalingam, PA Jänne, T Mok, K O'Byrne… - The lancet …, 2014 - thelancet.com
Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …
被引用次数：155 相关文章

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

SS Ramalingam, PA Jänne, T Mok, K O'Byrne… - The Lancet …, 2014 - Elsevier
Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

[引用][C] Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind …

SS Ramalingam, PA Jänne, T Mok, K O'Byrne… - The Lancet …, 2014 - cir.nii.ac.jp
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell
lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial | CiNii Research …

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial …

SS Ramalingam, PA Jänne, T Mok, K O'Byrne… - The Lancet …, 2014 - europepmc.org
Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

SS Ramalingam, PA Jänne, T Mok, K O'Byrne… - The Lancet …, 2014 - infona.pl
Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor. Findings from a
phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib …

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

SS Ramalingam, PA Jänne, T Mok… - The Lancet …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial

SS Ramalingam, PA Jänne, T Mok… - The Lancet …, 2014 - eprints.qut.edu.au
Background: Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

SS Ramalingam, PA Jänne, T Mok, K O'Byrne… - Lancet Oncol, 2014 - thelancet.com
Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

[引用][C] Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind …

SS Ramalingam, PA Jänne, T Mok, K O'Byrne… - Lancet …, 2014 - Elsevier Limited